Some examples include UCAs targeted to prostate specific membrane antigen (PSMA) for use in imaging prostate cancer [11,12], and BR55, a MB-based agent targeted to vascular endothelial growth factor receptor 2 (VEGFR2), a hallmark of tumor-associated angiogenesis [13,14]. This evidence concerns the gene FOLH1 and neoplasm.